CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery
NCT00925756
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
1. HIV-1 infection
2. All available CD4+ T cell counts within the last 12 months of screening below 350 cells/mm3 (minimum of 3 values obtained > 30 days apart).
3. HIV treatment with a stable (for at least 6 months) antiretroviral regimen consisting of at least 2 NRTIs and either a protease inhibitor boosted with low dose ritonavir or an NNRTI. A stable regimen is defined as no additions or deletions for more than 14 cumulative days.
4. Patient considered to be receiving initial HIV regimen (history of medication substitution for toxicity is allowed).
5. All available plasma HIV RNA levels within the last 12 months are below the level of detection. Isolated values that are detectable but < 1000 copies will be allowed as long as the plasma HIV RNA levels before and after this detectable time point are undetectable - The subject should have a minimum of 3 values obtained > 30 days apart.
6. Females of childbearing potential must have a negative serum pregnancy test at screening and agree to use a double-barrier method of contraception throughout the study period.
7. Men and women age ≥ 18 years.
1. Current antiretroviral regimen contains tenofovir disoproxil fumarate AND didanosine
in combination.
2. History of chronic hepatitis C (defined as HCV antibody positive and HCV RNA
detectable).
3. History of chronic active hepatitis B (defined as surface antibody negative, surface
antigen positive and HBV DNA detectable).
4. Concurrent use of G-CSF or GM-CSF.
5. Prior or concurrent use of IL-2.
6. Prior or concurrent use of a CCR5 inhibitor.
7. Active drug or alcohol use or dependence that, in the opinion of the investigator,
would interfere with adherence to study requirements.
8. Use of any immunomodulator, HIV vaccine, or investigational therapy within 30 days of
study entry.
9. Use of human growth hormone within 30 days prior to study entry.
10. Initiation of testosterone or anabolic steroids within 30 days prior to study entry.
(Exception: Chronic replacement dosages in patient's with diagnosed hypogonadism is
allowed).
11. Evidence of splenic sequestration or suppressed bone marrow function:
- Clinical or radiographic evidence of significant splenomegaly.
- History of leukemia or lymphoma.
- History of myelosuppressive chemotherapy or irradiation
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Honolulu, Hawaii
- Philadelphia, Pennsylvania
- New York, New York
- Amsterdam,
- Amsterdam,
- Amsterdam,
- Arnhem,
- Haarlem,
- Leiden,
- Rotterdam,
- Rotterdam,
- Tilburg,
- Utrecht,
Descriptive Information | |||||||
---|---|---|---|---|---|---|---|
Brief Title ICMJE | CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery | ||||||
Official Title ICMJE | The Impact of CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery and Gene Expression Profiles in HIV-Infected Patients With Viral Suppression | ||||||
Brief Summary | CCTG 590 is a open-label study to evaluate the impact of therapy intensification with Maraviroc (MVC) (a CCR5 inhibitor) to a stable suppressive HIV antiretroviral regimen on the rate of CD4+ T-cell recovery and gene expression profiles. Patients on a stable first-line HIV regimen with continued viral suppression and sub-optimal CD4+ T-cell counts will be eligible for this study. Those who are found to be eligible will have MVC (dose-adjusted to background HIV regimen) added to their current HIV regimen for 24 weeks. After the 24 week intensification, the MVC will be discontinued, the original antiretroviral regimen will be continued and the subjects will be followed for an additional 12 weeks. The investigators hypothesize that MVC will improve the rate of CD4 recovery. This improved CD4 recovery will be associated with favorable changes in gene expression profiles of genes involved with CD4 maintenance and circulation. | ||||||
Detailed Description | Blunted CD4+ T-cell responses during viral control may be a consequence of on-going T-cell destruction in the regenerative phase of CD4 recovery from activation-induced apoptosis and/or reduced production from decreased thymic output. Maraviroc, a CCR5 inhibitor, may improve the clinical status of HIV-infected by two distinct mechanisms. First, by blocking HIV entry into CD4+ T-cells, CCR5 inhibitors have direct antiviral activity. Second, as the pro-inflammatory state of HIV infection up-regulates CCR5 ligands and receptors, this CCR5 receptor antagonist may abrogate immune activation and resultant T-cell apoptosis. Importantly, MVC binds CCR5 receptors without inducing intracellular signaling or altering cell-surface expression. Potentially, MVC intensification during viral suppression with ART may further decrease persistent activation-induced apoptosis and improve repair and remodeling of lymphoid tissue leading to increased CD4+ T-cell recovery and function. The aim of this study is to evaluate a potentially therapeutic immunomodulatory effect of MVC. Several measures of immune homeostasis will be determined in this study, including functional genomic analysis and extended T-cell phenotyping. Genes responsive to MVC therapy will be identified and categorized into functional groups. Based upon existing literature of the identified genes and observed immune responses (change in CD4/CD8 subsets) during MVC therapy, a model of CCR5 responsive-genes and potential impact on immune recovery will be outlined. Potentially, individuals experiencing immune discordance during suppressive ART may be better treated by MVC antiretroviral intensification. 1. We hypothesize that expression will decrease among genes involved in immune activation (NF-kB, MAPK, nuclear factor of activated T-cells, MYD88 and STAT1), apoptosis (Fas ligand and TRAIL) and trafficking/repopulation of T-cells (CCR5, MIP-1?, MIP-1? and RANTES) and increase among genes involved in tissue repair (platelet-derived growth factor, insulin-like growth proteins and osteoblast-specific transcription factor).
| ||||||
Study Type ICMJE | Interventional | ||||||
Study Phase ICMJE | Phase 4 | ||||||
Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment | ||||||
Condition ICMJE | HIV Infections | ||||||
Intervention ICMJE | Drug: Maraviroc
Maraviroc will be given dose-adjusted to background HIV treatment (150 mg, 300 mg, or 600 mg twice daily) Other Name: Selzentry | ||||||
Study Arms ICMJE | Experimental: Maraviroc 150 mg, 300 mg, or 600 mg twice daily
This was a single arm study where Maraviroc was added for 24 weeks. Maraviroc was dose-adjusted for concomitantly administered HIV medications according to the manufacture's recommendations: 150 mg twice daily with strong CYP3A4 inhibitors, including:
Intervention: Drug: Maraviroc | ||||||
Publications * | Not Provided | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||||
Recruitment Information | |||||||
Recruitment Status ICMJE | Completed | ||||||
Actual Enrollment ICMJE | 32 | ||||||
Original Estimated Enrollment ICMJE | 30 | ||||||
Actual Study Completion Date ICMJE | April 11, 2014 | ||||||
Actual Primary Completion Date | May 2, 2012 (Final data collection date for primary outcome measure) | ||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| ||||||
Sex/Gender ICMJE |
| ||||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||||
Accepts Healthy Volunteers ICMJE | No | ||||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||
Listed Location Countries ICMJE | United States | ||||||
Removed Location Countries | |||||||
Administrative Information | |||||||
NCT Number ICMJE | NCT00925756 | ||||||
Other Study ID Numbers ICMJE | CCTG 590 | ||||||
Has Data Monitoring Committee | No | ||||||
U.S. FDA-regulated Product | Not Provided | ||||||
IPD Sharing Statement ICMJE | Not Provided | ||||||
Responsible Party | Sheldon Morris, University of California, San Diego | ||||||
Study Sponsor ICMJE | University of California, San Diego | ||||||
Collaborators ICMJE |
| ||||||
Investigators ICMJE |
| ||||||
PRS Account | University of California, San Diego | ||||||
Verification Date | August 2020 | ||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |